Analysts Offer Predictions for Pharming Group Q2 Earnings

Pharming Group (NASDAQ:PHAR - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Pharming Group in a research note issued on Thursday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.20) per share for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a "Buy" rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group's Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.60 EPS.

Separately, Oppenheimer increased their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th.

Pharming Group Stock Up 3.0%

Shares of PHAR traded up $0.29 during midday trading on Monday, hitting $10.00. The company had a trading volume of 3,303 shares, compared to its average volume of 6,481. The company's 50-day simple moving average is $8.52 and its 200-day simple moving average is $8.72. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm has a market capitalization of $680.31 million, a P/E ratio of -38.46 and a beta of -0.08. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.07.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.03. The business had revenue of $79.09 million during the quarter, compared to analysts' expectations of $67.74 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.